Monitor the bankruptcy court auction for competing bids and the November 14, 2026 PDUFA date for FDA approval. If approved, IGALMI could become a meaningful new revenue stream for Teva's neuroscience portfolio, but the deal is not yet final and carries execution risk.
Drug in focus
TEVA drug pipeline →BXCL-501
● Neutral Named in this press release- Impact
- Phase
- Approved (in-hospital); sNDA under FDA review for at-home use
- Time to market
- Already approved as IGALMI for in-hospital use. The at-home label expansion decision is due by November 14, 2026 PDUFA date. If approved, commercial launch for at-home use would follow shortly after, led by Teva.
- Next catalyst
- None dated
What to watchThe PDUFA decision on November 14, 2026 is the key catalyst. An approval would validate Teva's $57.5M acquisition and open a first-to-market at-home agitation market. A CRL would be a setback but not devastating for Teva given its diversified portfolio. Watch for any FDA AdComm announcement or pre-PDUFA news flow in the coming days.
How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Aug 28 $36.44entry
- T+1 · 3mo ago −1.07%α −0.77% · $36.05
- T+5 · 2mo ago −0.22%α −0.33% · $36.36
- T+20 · 7w ago +7.55%α +7.04% · $39.19
- T+55 · todayOpen
- T+60 · in 6d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Teva announced a stalking-horse bid to acquire BioXcel Therapeutics' IGALMI (dexmedetomidine sublingual film) and related assets for $57.5M upfront plus up to $67.5M in contingent payments, through a court-supervised bankruptcy sale. The asset is under FDA review for at-home use in agitation associated with schizophrenia or bipolar disorder, with a PDUFA date of November 14, 2026. If approved, this would be the first FDA-approved at-home treatment for this condition, expanding Teva's psychiatry portfolio.
Key Financial Metrics
Key Facts
- Teva is the stalking-horse bidder for BioXcel Therapeutics' IGALMI (dexmedetomidine sublingual film) in a Section 363 bankruptcy sale.
- Upfront payment of $57.5 million plus up to $67.5 million in contingent payments tied to FDA approval timing and sales milestones.
- PDUFA target action date for at-home use approval is November 14, 2026.
- If approved, IGALMI would be the first FDA-approved at-home treatment for agitation associated with schizophrenia or bipolar I/II disorder.
- Transaction remains subject to bankruptcy court approval, potential higher bids, and customary closing conditions.
- Teva would receive a break-up fee and expense reimbursement if not the successful bidder.
Financial Impact
Up to $125 million total consideration ($57.5M upfront + $67.5M contingent), with potential for significant upside if approved and commercialized.
Risk Factors
- Bankruptcy court may approve a higher bid from another party.
- FDA may not approve the at-home use indication by the PDUFA date or at all.
- Contingent payments depend on approval timing and sales milestones, which are uncertain.
- Integration and commercialization risks if the deal closes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3352601 |
Track record
61 reports on TEVA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 14 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $44.50 +3.10% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $44.50 0.00% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $44.50 0.00% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $44.50 +1.95% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $44.50 +2.91% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $44.50 +4.95% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $44.50 +4.95% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $44.50 +3.56% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $44.50 +3.56% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $44.50 +4.44% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers